- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04519866
Clinical Trial of Electroacupuncture in Axial Spondyloarthritis (E-AcuSpA) (E-AcuSpA)
A Randomized Controlled Trial of Electroacupuncture in the Management of Patients With Axial Spondyloarthritis in Singapore (E-AcuSpA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with active axial spondyloarthritis despite non-steroidal anti-inflammatory drugs (NSAIDs) or biologics, will be randomly allocated to receive electroacupuncture or manual acupuncture on a 1:1 basis via random permuted block randomization. All patients will receive their standard of care (drug therapy and physiotherapy) as background therapy. This study will not be investigating any therapeutic or medicinal products (drugs).
Primary outcome would be the mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between the 2 groups over 12 weeks (as assessed at weeks 0, 3, 6, 9, 12) adjusted for baseline covariate and other potential confounders. Patients will be followed up for BASDAI, other clinical, quality of life (QoL), economic outcomes as well as Traditional Chinese Medicine (TCM) syndrome scores over time for secondary and exploratory outcomes. A cost-effectiveness analysis will be performed. Adverse events will be recorded.
The primary hypothesis is that electroacupuncture may result in better disease activity control in patients with AxSpA as compared to manual acupuncture over 12 weeks, while secondary hypothesis is that electroacupuncture may result in greater improvements in other clinical and quality of life outcomes as compared to those receiving manual acupuncture over 24 weeks. The investigators also hypothesize that there is no difference in safety between both arms.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Warren Fong
- Phone Number: +65 63214028
- Email: warren.fong.w.s@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169608
- Recruiting
- Singapore General Hospital
-
Contact:
- Lay Lian Tan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 21 years of age or older
- Diagnosed with AxSpA according to the 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria
- Bath AS Disease Activity Index (BASDAI) score ≥4 on a 11-point Numerical Rating Scale (NRS)
- Failed 2 sequential NSAIDs (including cyclooxygenase-2 inhibitor) at maximal tolerated doses for ≥4 weeks in total
- Patients on concomitant biological therapy (e.g. tumour necrosis factor inhibitor therapy, anti-interleukin 17) or non-biologic disease-modifying antirheumatic drugs (DMARDs) (e.g. methotrexate (MTX) or sulfasalazine (SSZ) or leflunomide (LEF)) at study entry must be on the drug for ≥12 weeks and at stable dose for ≥4 weeks prior to randomisation
- Patients taking systemic corticosteroids have to be on stable dose of ≤10mg/day prednisolone or equivalent for at least two weeks before randomisation.
Exclusion Criteria:
- Pregnant or breastfeeding women
- With bleeding disorders
- With blood-borne communicable diseases (e.g. hepatitis B, hepatitis C, human immunodeficiency virus, etc)
- With implantable electrical device (e.g. pacemaker)
- Suffering from impaired skin sensation or serious skin lesions along the vertebrae
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Electroacupuncture
In addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment.
Each treatment course will consist of 10 acupuncture sessions held over 5 weeks.
Patient will take a break of 5-7 days in between each course of acupuncture.
|
Manual acupuncture (see procedures below) will be administered first to obtain the "de qi" sensation. After "de qi" is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min. Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms. |
Active Comparator: Manual acupuncture
In addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment.
Each treatment course will consist of 10 acupuncture sessions held over 5 weeks.
Patient will take a break of 5-7 days in between each course of acupuncture.
|
After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve "de qi" (a compositional sensation including soreness, numbness, distention and heaviness). Acupoints used will be similar to those mentioned for electroacupuncture (see above). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between both groups
Time Frame: Week 3, 6, 9, 12
|
Mean difference in BASDAI score between both groups from baseline to weeks 3, 6, 9 and 12. BASDAI score ranges from 0-10, with higher scores indicating higher disease activity. |
Week 3, 6, 9, 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean difference in Bath Ankylosing Spondylitis Functional Index (BASFI) score between both groups
Time Frame: Week 6, 12, 24
|
Mean difference in BASFI score between both groups from baseline to weeks 6, 12 and 24. BASFI score ranges from 0-10, with higher scores indicating poorer functioning. |
Week 6, 12, 24
|
Mean difference in Bath Ankylosing Spondylitis Patient Global score (BAS-G) between both groups
Time Frame: Week 6, 12, 24
|
Mean difference in BAS-G score between both groups from baseline to weeks 6, 12 and 24. BAS-G score ranges from 0-10, with higher scores reflecting poorer well-being. |
Week 6, 12, 24
|
Mean difference in Assessment of Spondyloarthritis International Society Health Index (ASAS HI) score between both groups
Time Frame: Week 6, 12, 24
|
Mean difference in ASAS HI score between both groups from baseline to weeks 6, 12 and 24. ASAS HI score ranges from 0-17, with higher scores indicating poorer health status. |
Week 6, 12, 24
|
Mean difference in Ankylosing Spondylitis Quality of Life (ASQoL) score between both groups
Time Frame: Week 6, 12, 24
|
Mean difference in ASQoL score between both groups from baseline to weeks 6, 12 and 24. ASQoL score ranges from 0-18, with higher scores indicating worse quality of life. |
Week 6, 12, 24
|
Mean difference in EuroQol- 5 Dimension (EQ-5D) score between both groups
Time Frame: Week 6, 12, 24
|
Mean difference in EQ-5D score between both groups from baseline to weeks 6, 12 and 24. EQ-5D consists of a descriptive system and a visual analogue scale. The descriptive system covers 5 dimensions: mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. Each dimension has a minimum and maximum score of 1 and 5 respectively, with higher scores representing a greater problem in that dimension. The visual analogue scale ranges from 0-100, with lower scores indicating poorer health status. |
Week 6, 12, 24
|
Mean difference in Work Productivity and Activity Impairment (WPAI) score between both groups
Time Frame: Week 6, 12, 24
|
Mean difference in WPAI score between both groups from baseline to weeks 6, 12 and 24. WPAI measures absenteeism, presenteeism, work productivity loss and activity impairment. These are expressed as percentages, from 0-100, with higher numbers indicating greater impairment and less productivity. |
Week 6, 12, 24
|
Mean difference in healthcare costs between both groups
Time Frame: Week 6, 12, 24
|
Mean difference in healthcare costs will be assessed for both groups at weeks 6, 12 and 24.
|
Week 6, 12, 24
|
Mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between both groups
Time Frame: Week 24
|
Mean difference in BASDAI score between both groups from baseline to week 24.
BASDAI score ranges from 0-10, with higher scores indicating higher disease activity.
|
Week 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between both groups
Time Frame: Week 52
|
Mean difference in BASDAI score between both groups from baseline to week 52.
BASDAI score ranges from 0-10, with higher scores indicating higher disease activity.
|
Week 52
|
Mean difference in Bath Ankylosing Spondylitis Functional Index (BASFI) score between both groups
Time Frame: Week 52
|
Mean difference in BASFI score between both groups from baseline to week 52.
BASFI score ranges from 0-10, with higher scores indicating poorer functioning.
|
Week 52
|
Mean difference in Bath Ankylosing Spondylitis Patient Global score (BAS-G) between both groups
Time Frame: Week 52
|
Mean difference in BAS-G score between both groups from baseline to week 52.
BAS-G score ranges from 0-10, with higher scores reflecting poorer well-being.
|
Week 52
|
Mean difference in Assessment of Spondyloarthritis International Society Health Index (ASAS HI) score between both groups
Time Frame: Week 52
|
Mean difference in ASAS HI score between both groups from baseline to week 52.
ASAS HI score ranges from 0-17, with higher scores indicating poorer health status.
|
Week 52
|
Mean difference in Ankylosing Spondylitis Quality of Life (ASQoL) score between both groups
Time Frame: Week 52
|
Mean difference in ASQoL score between both groups from baseline to week 52.
ASQoL score ranges from 0-18, with higher scores indicating worse quality of life.
|
Week 52
|
Mean difference in EuroQol- 5 Dimension (EQ-5D) score between both groups
Time Frame: Week 52
|
Mean difference in EQ-5D score between both groups from baseline to week 52.
EQ-5D consists of a descriptive system and a visual analogue scale.
The descriptive system covers 5 dimensions: mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression.
Each dimension has a minimum and maximum score of 1 and 5 respectively, with higher scores representing a greater problem for that dimension.
The visual analogue scale ranges from 0-100, with lower scores indicating poorer health status.
|
Week 52
|
Mean difference in Work Productivity and Activity Impairment (WPAI) score between both groups
Time Frame: Week 52
|
Mean difference in WPAI score between both groups from baseline to week 52.
WPAI measures absenteeism, presenteeism, work productivity loss and activity impairment.
These are expressed as percentages, from 0-100, with higher numbers indicating greater impairment and less productivity.
|
Week 52
|
Mean difference in healthcare costs will be assessed for both groups
Time Frame: Week 52
|
Mean difference in healthcare costs will be assessed for both groups at week 52.
|
Week 52
|
Mean difference in Traditional Chinese Medicine (TCM) syndrome scores will be assessed for both groups
Time Frame: Week 3, 6, 9, 12
|
Mean difference in TCM syndrome scores will be assessed for both groups at weeks 0, 3, 6, 9, and 12. In this study, the main TCM syndromes are: 1) Yang" deficiency in kidneys and "Du" meridian, 2) Deficiency in liver and kidney, 3) Blockage due to stagnated blood, 4) Blockage due to damp heat syndrome, and 5) Blockage due to damp cold syndrome. Each symptom under the syndromes has a minimum score of 0 and maximum score of 3, with higher scores indicating greater symptom severity. Scores would be added up to tabulate syndrome scores, with higher scores indicating greater syndrome severity. |
Week 3, 6, 9, 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Warren Fong, Singapore General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/2435
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spondylarthritis
-
University Hospital, GhentJanssen Biologics B.V.Completed
-
AbbVieActive, not recruitingAxial Spondylarthritis (axSpA)Argentina, Australia, Belgium, Bulgaria, Canada, France, Greece, Hungary, Israel, Kuwait, Mexico, Poland, Russian Federation, Spain, Switzerland, United Arab Emirates
-
CHU de ReimsUnknown
-
AbbVieRecruitingAxial Spondylarthritis (r-axSpA)Germany
-
University of LeedsCentocor, Inc.Terminated
-
Spanish Clinical Pharmacology SocietySpanish reumatology SocietyCompleted
-
PfizerCompleted
-
Centre Hospitalier Universitaire de NīmesAssistance Publique Hopitaux De Marseille; University Hospital, MontpellierRecruiting
-
Diakonhjemmet HospitalRecruiting
-
Centre Hospitalier Universitaire de NiceRecruiting
Clinical Trials on Electroacupuncture
-
The Second Affiliated Hospital, Guangzhou University...RecruitingDisorder of Consciousness | ElectroacupunctureChina
-
University of California, IrvineRecruiting
-
Guang'anmen Hospital of China Academy of Chinese...Shenzhen Second People's Hospital; Shaanxi Hospital of Traditional Chinese... and other collaboratorsUnknown
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Tianjin Nankai HospitalRecruitingSepsis | Electroacupuncture | Sepsis-associated Brain InjuryChina
-
Cancer Institute and Hospital, Chinese Academy...UnknownAcupuncture | Gastrointestinal FunctionChina
-
Corporacion Parc TauliCompletedFatigue | Inflammatory Bowel DiseaseSpain
-
Guang'anmen Hospital of China Academy of Chinese...Not yet recruitingDysmenorrhea | Adenomyosis | ElectroacupunctureChina
-
Guang'anmen Hospital of China Academy of Chinese...RecruitingChronic Urinary RetentionChina
-
Guang'anmen Hospital of China Academy of Chinese...Ministry of Science and Technology of the People´s Republic of ChinaCompletedMenopausal SyndromeChina